At Biogen Idec, Inc. (Massachusetts), It's Crunch Time for CEO
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Since becoming Biogen Idec Inc.'s BIIB -1.93% chief executive three years ago, George Scangos has helped quadruple the company's market value as expectations built for its latest multiple-sclerosis drug. Now, he is under pressure to deliver on those hopes by successfully guiding the biggest product launch of his career. Biogen's new pill, Tecfidera, is the most-anticipatedtreatment for multiple sclerosis in more than 15 years, doctors say. After nearly three months on the market, prescription data indicate that the drug is on track to top analysts' estimates this year and achieve at least $1 billion in annual sales by the end of 2014. But some bumps have appeared in the road.
Help employers find you! Check out all the jobs and post your resume.
Since becoming Biogen Idec Inc.'s BIIB -1.93% chief executive three years ago, George Scangos has helped quadruple the company's market value as expectations built for its latest multiple-sclerosis drug. Now, he is under pressure to deliver on those hopes by successfully guiding the biggest product launch of his career. Biogen's new pill, Tecfidera, is the most-anticipatedtreatment for multiple sclerosis in more than 15 years, doctors say. After nearly three months on the market, prescription data indicate that the drug is on track to top analysts' estimates this year and achieve at least $1 billion in annual sales by the end of 2014. But some bumps have appeared in the road.
Help employers find you! Check out all the jobs and post your resume.